Christophe Weber, Takeda CEO (Kosuke Okahara/Bloomberg via Getty Images)
July 31, 2024 01:21 PM EDT
R&D
Pharma

Take­da de­fends Alzheimer's pact, TYK2 po­ten­tial as re­struc­tur­ing is in 'full swing'

Kyle LaHucik

Senior Reporter

In its quar­ter­ly up­date on Wednes­day, Take­da ex­ec­u­tives said the Japan-based phar­ma gi­ant’s $900 mil­lion re­struc­tur­ing is in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

Paragon launch­es an­oth­er com­pa­ny in hot PD-1xVEGF space that goes straight to re­verse merg­er

Pfiz­er rais­es earn­ings guid­ance in re­but­tal to ac­tivist Star­board

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

Ex­clu­sive: Gen­mab lines up T cell en­gager pact with Re­vi­tope

WuXi AppTec is still sign­ing on new clients de­spite Biose­cure threat

A service from the Financial Times